- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Liminatus Pharma Inc.: Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy | 277 | GlobeNewswire (Europe) | FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced... ► Artikel lesen | |
| 18.08. | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock | 186 | GlobeNewswire (Europe) | FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving... ► Artikel lesen | |
| 18.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Liminatus Pharma wechselt an den Nasdaq Capital Market | 2 | Investing.com Deutsch | ||
| 13.08. | Liminatus Pharma moves to Nasdaq Capital Market | 4 | Investing.com | ||
| 13.08. | Liminatus Pharma Inc.: Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement | 423 | GlobeNewswire (Europe) | FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies for cancer and other... ► Artikel lesen | |
| 04.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.07. | Liminatus Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Liminatus amends InnocsAI merger, closing set for July 2 | 2 | Investing.com | ||
| 30.06. | Liminatus Pharma Inc.: Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline | 707 | GlobeNewswire (Europe) | FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced... ► Artikel lesen | |
| 24.06. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 03.06. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Liminatus Pharma secures $1.9M cash via warrant exercises | 1 | Seeking Alpha | ||
| 22.05. | Liminatus Pharma faces Nasdaq delisting after compliance failure | 2 | Investing.com | ||
| 22.05. | Liminatus Pharma Inc.: Liminatus Pharma Announces Nasdaq Delisting Notification | 383 | GlobeNewswire (Europe) | FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that the Company received a delisting notice from The Nasdaq... ► Artikel lesen | |
| 21.05. | Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI | 5 | FierceBiotech | ||
| 21.05. | Liminatus Pharma Is Trending Overnight - Here's Why LIMN Stock Surged Over 79% In After-Hours Session | 2 | Benzinga.com | ||
| 20.05. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Liminatus Pharma, Inc. - 10-K, Annual Report | - | SEC Filings |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech-Aktie: Gibt sie jetzt weiter Vollgas? | Die BioNTech-Aktie hat mit einer Kursexplosion von rund +25% auf 116,57 US$ in der vergangenen Woche mächtig für Aufsehen gesorgt. Jetzt stellt sich die Frage: Bleibt sie auf dem Gaspedal? Was ein Wettbewerber... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | AWSX der Telegram-Trader.de: Gilead:Trodelvy bekommt in Europa deutlich mehr Gewicht-Wo liegen die Kursziele? | ||
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
LIMINATUS PHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,250 Euro und damit +0,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.